Sven Wehrwein, an insider at AtriCure Inc (ATRC), sold 34,374 shares of the company's stock on November 23, 2025, at a price of $37.32 per share, totaling $1.28 million. Following this transaction, Wehrwein retains 34,374 shares in AtriCure.
AtriCure, headquartered in Mason, Ohio, focuses on developing surgical ablation systems for cardiac tissue. The company also offers products for left atrial appendage management and pain management solutions. AtriCure has a market capitalization of $1.6 billion and reported an EPS of -0.62 as of November 18, 2025. Upcoming earnings are scheduled for July 27, 2026, with an estimated EPS of -0.04 and revenue of $155.3 million.
Insider transactions, such as this sale, are reported to the SEC and can provide insights into executives' perspectives on their company’s stock. However, such activity should be considered alongside other financial indicators and market conditions, as a single transaction may not reflect broader company sentiment.
Investors are advised to analyze patterns of insider trading over time rather than focusing solely on isolated events.